We developed a variant database for diabetes syndrome genes, using the Leiden Open Variation Database platform, containing observed phenotypes matched to the genetic variations. We populated it with 628 published disease-associated variants (December 2016) for: WFS1 (n = 309), CISD2 (n = 3), ALMS1 (n = 268), and SLC19A2 (n = 48) for Wolfram type 1, Wolfram type 2, Alström, and Thiamine-responsive megaloblastic anemia syndromes, respectively; and included 23 previously unpublished novel germline variants in WFS1 and 17 variants in ALMS1. We then investigated genotype-phenotype relations for the WFS1 gene. The presence of biallelic loss-of-function variants predicted Wolfram syndrome defined by insulin-dependent diabetes and optic atrophy, with a sensitivity of 79% (95% CI 75%-83%) and specificity of 92% (83%-97%). The presence of minor loss-of-function variants in WFS1 predicted isolated diabetes, isolated deafness, or isolated congenital cataracts without development of the full syndrome (sensitivity 100% [93%-100%]; specificity 78% [73%-82%]). The ability to provide a prognostic prediction based on genotype will lead to improvements in patient care and counseling. The development of the database as a repository for monogenic diabetes gene variants will allow prognostic predictions for other diabetes syndromes as next-generation sequencing expands the repertoire of genotypes and phenotypes.
INTRODUCTION
Monogenic diabetes syndromes are characterized by glucose intolerance together with extrapancreatic features, and result from one or more defects in a single gene. There are about 40 different genetic subtypes identified so far, with an estimated prevalence of 2%-5% of all patients with diabetes (Schwitzgebel, 2014) . The wide phenotypic and genetic heterogeneity poses significant problems for our understanding of disease mechanisms, and for providing prognostic information. This is compounded by the identification of diabetes syndrome gene variants of uncertain significance, in isolated diabetes through the widespread application of next-generation sequencing (Alkorta-Aranburu et al., 2014; Ellard et al., 2013; Philippe et al., 2015) . There are no up-to-date variant databases for most monogenic diabetes syndrome genes; those that do exist contain limited historical variants on publicly available Websites (HGVS: http://www.hgvs.org/ dblist/dblist.html, GEN2PHEN: http://www.gen2phen.org/data/lsdbs, LOVD: http://grenada.lumc.nl/LSDB_list/lsdbs, WAVe: http://bioin formatics.ua.pt/WAVe, ClinVar: http://www.ncbi.nlm.nih.gov/clinvar).
Wolfram (type 1, MIM# 222300; type 2, MIM# 604928), Alström (MIM# 203800) , and Thiamine-responsive megaloblastic anemia (MIM# 249270) syndromes are rare, monogenic syndromes where diabetes is a common feature. They are chronically debilitating, highly complex, and in common with other rare diseases, often subject to misdiagnosis, delayed diagnosis, and nondiagnosis. The syndromes exhibit clinical overlap: all can cause profound visual and hearing impairment, and diabetes mellitus (DM) or impaired glucose tolerance. With 0.57, 0.14, and 0.1 cases per 100,000 (Prevalence of rare diseases: Bibliographic data, 2013), all three syndromes also fall within the EU rare disease definition of "a prevalence of not more than 5 affected persons is an EU initiative to widen access to genetic testing, clinical information, and research for the overlapping rare diabetes syndromes Wolfram, Alström, Bardet Biedl syndrome, and others, in Europe (www.euro-wabb.org). As part of this project, we have created a new locus-specific database to provide catalogs of gene variations involved in monogenic diabetes syndromes. By building on the existing generic frameworks and platforms for rare diseases, this gene variant database operates at a disease-specific level to support efficient diagnosis and research for these syndromic diabetes diseases.
THE GENES
This report focuses on four genes in the EURO-WABB locus-specific database, namely ALMS1, WFS1, CISD2, and SLC19A2.
Pathogenic variants in the gene ALMS1 (MIM# 606844) on chromosomes 2p13.1 have been identified in patients with Alström syndrome (AS), an autosomal-recessive disease characterized by retinal dystrophy, childhood obesity, type 2 DM, and sensorineural hearing loss (Collin et al., 2002; Hearn et al., 2002; Marshall et al., 2005; Marshall et al., 2007; Marshall et al., 2015) . Other features include dilated cardiomyopathy (70% of patients), hepatic diseases, and urological abnormalities (Alstrom, Hallgren, Nilsson, & Asander, 1959; Marshall et al., 2005; Marshall et al., 2007) . ALMS1 consists of 23 exons encompassing over 224 kb of genomic DNA encoding a centrosomal protein of 4,169 amino acids, which contain a large tandem-repeat domain consisting of 47 amino acids and has been implicated in the assembly and maintenance of primary cilia (Hearn et al., 2005; Knorz et al., 2010; Li et al., 2007) and in fibrosis (Zulato et al., 2011) .
Pathogenic variants in WFS1 (MIM# 606201) cause Wolfram syndrome (WS) type 1, a rare neurodegenerative disease characterized by DM and optic atrophy (OA). The gene is located on chromosome 4p16.1, and codes for an 890 amino acid protein (Wolframin) consisting of eight exons spanning 33.4 kb of genomic DNA (Inoue et al., 1998) . Wolframin is an endoplasmic reticulum (ER) membrane protein (Takeda et al., 2001 ), thought to function as ER calcium channel or a regulator of ER calcium channel activity (Osman et al., 2003) and is involved in the unfolded protein response via interaction with and regulation of the ER stress sensor ATF6 (Fonseca et al., 2010) . It is under regulation by ER stress sensors PERK, IRE 1-alpha, and ATF6-beta (Fonseca et al., 2005; Odisho, Zhang, & Volchuk, 2015) . WS type 1 is also known as DIDMOAD due to the clinical features associated with the disease (diabetes insipidus, diabetes mellitus, optic atrophy, and deafness). Although nonautoimmune insulin-dependent DM is the most common manifestation of WS, the most frequent cause of morbidity and mortality associated with the disease are neurological disorders and urinary tract complications (Kinsley, Swift, Dumont, & Swift, 1995) .
Pathogenic variants in the CISD2 gene (MIM# 611507) have been identified in patients with WS type 2 (Amr et al., 2007; Mozzillo et al., 2014) . WS type 2 differs from type 1 in respect that so far no diabetes insipidus (DI) and psychiatric disorder has been associated with the disease, and the novel presence of defective platelet aggregation leading to peptic ulcer bleeding. CISD2 is located on chromosome 4q24, and codes for a 135 amino acid protein ERIS (ER intermembrane small protein), which consists of three exons spanning a 64.7-kb genomic region.
ERIS is a highly conserved zinc finger protein of the ER membrane involved in the regulation of cellular calcium homeostasis and mitochondrial biogenesis (Wang et al., 2014) . Immunoprecipitation studies showed that ERIS protein coded by CISD2 does not interact with Wolfram protein (Amr et al., 2007) . Studies in mice show that cisd2 deficiency in these animals causes mitochondrial death and dysfunction accompanied by autophagic death (Chen et al., 2009 ). To date, only 13 individuals with CISD2 mutations have been reported in the literature (Amr et al., 2007; Mozzillo et al., 2014; Rondinelli, Novara, Calcaterra, Zuffardi, & Genovese, 2015) .
Thiamine-responsive megaloblastic anemia syndrome (TRMA syndrome) is a rare autosomal-recessive condition characterized by nonautoimmune DM (nontype 1), sensorineural hearing loss, and megaloblastic anemia. The gene responsible, SLC19A2 (MIM# 603941), is located on chromosome 1q24.2, consists of six exons with 497 amino acids spanning a 22.5-kb genomic region. It codes for a high affinity thiamine transporter (Diaz, Banikazemi, Oishi, Desnick, & Gelb, 1999; Dutta et al., 1999; Labay et al., 1999) . Although anemia can be corrected by thiamine treatment, the hearing loss is progressive and irreversible. In TRMA syndrome patients, DM and hearing loss can manifest from infancy to adolescence.
THE DATABASE
We followed the guidelines for establishing locus-specific databases (Celli, Dalgleish, Vihinen, Taschner, & den Dunnen, 2012; Vihinen, den Dunnen, Dalgleish, & Cotton, 2012) . We formed a consortium of scientists and clinicians working with these diseases through the EUfunded EURO-WABB European Registry project (Farmer et al., 2013 ).
The database is based on the Leiden Open-source Variation Database (LOVD) platform V2.0-36 (Fokkema et al., 2011) and stores both published and submitted variants.
Variations in the databases are named according to the HGVS nomenclature (Den Dunnen et al., 2016; http://varnomen.hgvs.org) and include descriptions at DNA and protein levels. Variants are numbered and described with respect to the NCBI reference sequences NM_015120.4 (NP_055935.4), NM_006005.3 (NP_005996.2), NM_001008388.4 (NP_001094344.1), NM_006996.2 (NP_008927.1) for ALMS1, WFS1, CISD2, and SLC19A2, respectively, with +1 = A of ATG start codon. Previously published variants that do not conform are renamed accordingly with the original description included in the entry to facilitate cross-reference. Mutalyzer (Wildeman, van Ophuizen, den Dunnen, & Taschner, 2008 ) is used to verify variant description.
We included the following minimum data item set: pathogenicity, DNA change, genomic position in the reference sequence and genome assembly (GRCh 38), predicted protein change, mutation type, variant remarks (other information available for the variant), technique used, link to published reference if applicable, and the following anonymized clinical data: ethnic origin, gender, consanguinity, and clinical features.
As standard for the LOVD system, the database has links to other services such as PubMed, HGNC, Entrez Gene, OMIM, and GeneCards, in addition to sequence databases. The databases catalogs variants identified in patients reported to have been diagnosed with AS, WS type 1/type 2, and TRMA syndrome.
In predicting variant pathogenicity, we followed guidelines from the American College of Medical Genetics and Genomics (ACMG) and the Association of Molecular Pathology (AMP) (Richards et al., 2015) and considered other supporting information such as experimental evidence, presence in multiple families, segregation with disease T r a n s l o c a t i o n s 1 0 0 0 phenotypes, as well as the prediction algorithm SIFT (Ng & Hanikoff, 2003) , and PolyPhen-2 (Sunyaev et al., 2001 ).
The database is implemented on a secure server held by University 
AS and WS patient recruitment and variant identification
Children and adult patients with AS were recruited to the DAS study (defining the phenotype in AS) (UKCRN 9044, REC approval 10/H0203/33). Children with AS, and children and adults with WS, were recruited to the EURO-WABB European Registry study (UK REC approval 11/WM/0127). Appropriate informed consent was obtained from adult patients and parents/guardians of children.
Assent was also obtained where possible from children under 16
years. Clinical histories and medical records were obtained for all participants.
Genomic DNA were extracted from peripheral blood lymphocytes using standard protocols. Sequencing of WFS1 and ALMS1 exons were performed using ABI 3730 automated sequencer (Applied Biosystems, Foster City, CA) after PCR amplifications.
Identified variants were checked against dbSNP, 1000 Genomes Project, or ExAC (exac.broadinstitute.org) for the more recent samples.
Novel variants in ALMS1 and WFS1
We report 17 novel germline ALMS1 variants detected in 17 UK AS patients from 16 families and one Slovakian patient ( p.His313Tyr mutation has been shown to be capable of causing WS (Hansen et al., 2005) and inducing ER stress (Bonnycastle et al., 2013) . One of our patients (WSUK-47) was also identified with the p.His313Tyr variant without the presence of another pathogenic WFS1 variant.
WFS1 genotype-phenotype analysis
We collected information on the age of onset of DM, OA, deafness, DI, and other reported clinical features from patients in the database and categorized the disease by phenotype and genotype.
Disease phenotype was classified as: (1) Table S1 ). We defined the WFS1 N-terminal as amino acids at positions 1-652 (cytosolic and transmembrane domain) and the C-terminal as amino acids at positions 653-890 (ER lumen) (Fig. 1) .
Patients whose phenotype could clearly be identified were then assigned into respective genotype and phenotype categories (Supp. F I G U R E 1 WFS1 variant distribution based on disease phenotype. Position of the amino acid involved in the disease phenotype is indicated by different shades. Position of the transmembrane regions were predicted based on TMHMM (Krogh, Larsson, von Heijne, & Sonnhammer, 2001) and SMART (Letunic, Doerks, & Bork, 2015 Notes: Group 1: variants predicted to cause complete or partial loss of function (N-terminal nonsense and frameshifts, splice-site variants predicted to cause exon skipping/deletions; C-terminal nonsense and frameshift; N-terminal small in-frame deletions/duplications/insertions/indels); or compound heterozygous where one variant is predicted to cause complete and the other a partial loss of function. Group 2: variants predicted to cause minor loss of function (missense, C-terminal small in-frame deletions/duplications/insertions/indels) or compound heterozygous for a variant predicted to cause partial and minor loss of function. See Supp. Group 1 6.3 ± 3.5 years 11.7 ± 5.7 years 14.4 ± 7.2 years 13.9 ± 6.7 years
Group 2 12.0 ± 9.9 years 15.8 ± 11.4 years 18.0 ± 13.7 years 18.0 ± 10.2 years n = 90 n = 81 n = 37 n = 29
Notes: Group 1: variants predicted to cause complete or partial loss of function (N-terminal nonsense and frameshifts, splice-site variants predicted to cause exon skipping/deletions; C-terminal nonsense and frameshift; N-terminal small in-frame deletions/duplications/insertions/indels); or compound heterozygous where one variant is predicted to cause complete and the other a partial loss of function. Group 2: variants predicted to cause minor loss of function (missense, C-terminal small in-frame deletions/duplications/insertions/indels) or compound heterozygous for a variant predicted to cause partial and minor loss of function.
UK-White European families. In these cases, we speculate that genetic and environmental interactions may contribute to variable expressivity.
Comparison of the age of onset of DM and OA in group 1 and group 2 genotypes revealed a highly significant difference in phenotypes between the two groups. The mean age of onset of DM was 6.3 ± 3.5 years in patients with group 1 genotypes and 12.0 ± 9.9 years in individuals with group 2 genotypes (P < 0.0001), whereas the mean age of onset of OA was 11.7 ± 5.7 years in individuals with group 1 genotypes and 15.8 ±11.4 years in individuals carrying group 2 genotypes (P = 0.0023). A significant difference in the age of onset of DI was also observed between individuals carrying group 1 and group 2 genotypes. The mean age of onset of DI was 13.9 ± 6 years and 18.0 ± 10 years in group 1 and group 2 genotypes (P = 0.047), respectively (Table 6) . Rohayem et al. (2011) and de Heredia, Clèries, and Nunes (2013) also showed significant differences in the age of onset of DM and DI among patients carrying predicted complete, partial, or minor loss-of-function mutation. However, due to differences in genotypic classification used by these authors, the mean age of onset of DM and DI cannot be directly compared. It has been previously reported that some patients harboring a homozygous frameshift variant in the C-terminal end of WFS1 tend to have a delayed onset of OA (Zalloua et al., 2008) . We therefore analyzed 19 patients carrying homozygous frameshift variants in the Cterminal of WFS1 (patients 265, 271-280, 285, 290, 295-298, 300 , and 301 in Supp. Table S1 ), and 33 patients harboring a homozygous frameshift variant in the N-terminal region (patients 14-21, 58, 63, 87-91, 104, 112, 116, 118, 119, 123, 135, 198, 202, 235, 243-247 , and 252-254 in Supp. Table S1 ). There is a slight difference in the age of onset of OA in patients with homozygous frameshift C-terminal variant compared with the age of OA onset in patients with homozygous frameshift N-terminal variants (13.2 ± 5 years and 11.2 ± 6.1 years, respectively). However, this is not statistically significant. Variants associated with a WS phenotype were distributed in both outside and inside the transmembrane region, whereas variants involved in the dominant form of WFS1-related disorder were mainly located at the C-terminal end of the protein (Fig. 1) .
Future prospects and database update
The clinical overlaps and complexity exhibited by the syndromes mentioned in this report may lead to delayed or misdiagnosis. We have demonstrated that a more detailed description of clinical phenotypes in the patients coupled with genotype information can provide insight into genotype-phenotype correlations of these syndromes. Unfortunately, the clinical phenotypes are difficult to access, not always available, and can be unreliable sometimes in terms of age of onset. We hope that the information available for some of the patients in our databases will allow for better understanding of the disease and reliable genetic counselling for the patients and their families. Ultimately, functional studies of the variants will be necessary to further our understanding of disease mechanisms that will lead to the development of personalized therapies.
The EURO-WABB LOVD locus-specific databases for 
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